Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved thera

Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved thera

HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a

Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report) has earned an average rating of "Hold" from

Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.10) per share which beat the analys

AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopha

Data support ongoing Phase 2 “RENEW” trial First-in-human clinical study produced measurable reducti

Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary F

AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (

Maxim Group analyst Jason McCarthy initiates coverage on Rein Therapeutics (NASDAQ:RNTX) with a B

Rein Therapeutics Inc. (RNTX) Shareholder/Analyst Call Prepared Remarks Transcript

Rein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimis

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) First patient

HC Wainwright & Co. analyst Brandon Folkes maintains Rein Therapeutics (NASDAQ:RNTX) with a B

Total gross proceeds increased to $57.5 million Offering consisted solely of common stock Proceeds e

Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.19) per share which beat the analys

Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates,

AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company")

 8 patients enrolled, with additional patients expected in the near termEnrollment initiated in Marc

Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries

REIN THERAPEUTICS, INC.30,000,000 Shares of Common StockWe are selling 30,000,000 shares of our comm

Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.11) per share which beat the analys

Shares of Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report) traded up 1.6% during trading on F

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pip

Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report)'s stock price traded down 0.8% during mid-da

Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.21) per share which beat the analys

Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipe

Rein Therapeutics (NASDAQ:RNTX) stock is trading higher on Monday, with a session volume of 41.2 mil

Rein Therapeutics shares rise after the FDA lifts clinical hold on its Phase 2 RENEW trial for idiop

Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipe

FDA lifts clinical hold following review of Company's Complete Response submission.Company expec

AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopha

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Rein Therapeutics (NASDAQ:RN

AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a bioph

Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipe

AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceut

AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopha

Aileron Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.28) per share which missed the a

Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipe

Meeting adjourned to Wednesday, July 23, 2025 at 9:00 a.m. Eastern Time AUSTIN, Texas , June 24, 202